The action of ovarian hormones in cardiovascular disease

Biological Research

Volumn 36, Issue 3-4, 2003, Pages 325-341

  Medina, Rodolfo A ^a   Aranda, Evelyn ^b   Verdugo, Cesar ^b   Kato, Sumie ^b   Owen, Gareth I ^b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Atherosclerosis cardiovascular disease; Estrogen; Hormone replacement therapy (HRT); Myocardial infarction; Oral contraceptives; Progestins; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7A; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; BLOOD; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; FIBRINOLYSIS; GENETIC PREDISPOSITION; HEART INFARCTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUAL DEVELOPMENT; STROKE; VEIN THROMBOSIS;

EID: 0242456285     PISSN: 07169760     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-97602003000300005     Document Type: Review

References (118)

1. ACS N, VAJO Z, MIKLOS Z, SIKLOSI G, PAULIN F, FELICETTA JV, SZEKACS B (2002) The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies. Gynecol Endocrinol 16: 335-346
2. ADAMS MR, KAPLAN JR, MANUCK SB, KORITNIK DR, PARKS JS, WOLFE MS, CLARKSON TB (1990) Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys: Lack of an effect of added estrogen. Arteriosclerosis 10: 1051-1057
3. ADAMS MR, REGISTER TC, GOLDEN DL, WAGNER JD, WILLIAMS JK (1997) Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Throm Vasc Biol 17: 217-221
4. ANANYEVA NM, KOUIAVSKAIA DV, SHIMA M, SAENKO EL (2002) Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood 99: 4475-4485
5. ARDISSINO D, MERLINI PA, ARIENS R, COPPOLA R, BRAMUCCI E, MANNUCCI PM (1997) Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349: 769-771
6. BADIMON JJ, LETTINO M, TOSCHI V, FUSTER V, BERROZPE M, CHESEBRO JH, BADIMON L (1999) Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99: 1780-1787
7. BAUER KA (2002) Hormone replacement therapy and the factor V Leiden mutation. Arterioscler Thromb Vasc Biol 22: 879-880
8. BERGER GS, FOWLER WC (1997) Exogenous estrogens and endometrial carcinoma: review and comments for the clinician. J Reprod Med 18: 177-180
9. BILORA F, BOCCIOLETTI V, ZANON E, PETROBELLI F, GIROLAMI A (2001) Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost 7: 311-313
10. BJORKERUD S, BJORKERUD B (1996) Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 149: 367-380
11. BLADBJERG EM, SKOUBY SO, ANDERSEN LF, JESPERSEN J (2002) Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 17: 3235-3241
12. BLOEMENKAMP KW, HELMERHORST FM, ROSENDAAL FR, VANDENBROUCKE JP (2003) Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol 17: 509-528
13. BLOEMENKAMP KW, ROSENDAAL FR, HELMERHORST FM, VANDENBROUCKE JP (2000) Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 160: 49-52
14. BOMBELI T, KARSAN A, TAIT JF, HARLAN JM (1997) Apoptotic vascular endothelial cells become procoagulant. Blood 89: 2429-2442
15. BORN GVR, TIGGLE DJ, POOLE-WILSON PA (1991) Calcium and atherosclerosis. In: BORN GVR, TIGGLE DJ, POOLE-WILSON PA (eds) Calcium Antagonism and Atherosclerosis. London: Science Press. pp: 1-25
16. BRAND K, BANKA CL, MACKMAN N, TERKELTAUB RA, FAN ST, CURTISS LK (1994) Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 14: 790-797
17. CANO A, VANBAAL WM (2001) The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 40: 17-38
18. CASTELLI WP (1996) Lipids, risk factors and ischemic heart disease. Atherosclerosis 124: S1-S9
19. 2+ mobilization. Circ Res 81: 855-892
20. CROOK D (2001) Do we need clinical trials to test the ability of transdermal HRT to prevent coronary heart disease? Curr Control Trials Cardiovasc Med 2: 211-214
21. CUSHMAN M, MEILAHN EN, PSATY BM, KULLER LH, DOBS AS, TRACY RP (1999) Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19: 893-899
22. DAVIES MJ (1996) Stability and instability: the two faces of coronary atherosclerosis. The Paul Dudley White Lecture, 1995. Circulation 94: 2013-2020
23. DAVIES MJ, WOOLF N (1993) Atherosclerosis: what is it and why does it occur? Br Heart J 69: S3-S11
24. DECATERINA R, LIBBY P, PENG HB, THANNICKAL VJ, RAJAVASHISTH TB, GIMBRONE MA, SHIN WS, LLAO JK (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96: 60-68
25. DOUGLAS PS, KATZ SE, WEINBERG EO, CHEN MH, BISOP SP, LORELL BH (1998) Hypertrophic remodeling: gender differences in early response to left ventricular pressure overload. J Am Coll Cardiol 32: 1118-1125
26. DUBAL DB, ZHU H, YU J, RAU SW, SHUGHRUE PJ, MERCHENTHALER I, KINDY MS, WISE PM (2001) Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 98: 1952-1957
27. ESPELAND MA, MARCOVINA SM, MILLER V, WOOD PD, WASILAUSKAS C, SHERWINR, SCHROTT H, BUSH TL (1998) Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI investigators. Postmenopausal estrogen/progestin interventions. Circulation 97: 979-986
28. FARMER RD, LAWRENSON RA (1998) Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany. Am J Obstet Gynecol 179: S78-86
29. FEI H, BERLINER JA, PARHAMI F, DRAKE TA (1993) Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb 13: 1711-1717
30. GIARDINA EG (2000) Heart disease in women. Int J Fertil Womens Med. 45: 350-357
31. GILBERT GE, ARENA AA (1996) Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem 271: 11120-11125
32. GORDON EM, DOUGLAS J, RATNOFF OD (1983) Influence of augmented Hageman factor (Factor XII) titers on the cryoactivation of plasma prorenin in women using oral contraceptive agents. J Clin Invest 72: 1833-1838
33. GRIFFIN JH, KOJIMA K, BANKA CL, CURTISS LK, FERNANDEZ JA (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103: 219-227
34. GU L, OKADA Y, CLINTON SK, GERARD C, SUKHOVA GK, LIBBY P, ROLLINS BJ (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281
35. GUETTA V, CANNON RO (1996) Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 93: 1928-1937
36. HAARBO J, SVEDSEN OL, CHRISTIANSEN C (1991) Estrogen monotherapy and combined estrogen-progestin replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 87: 274-279
37. HARRIS GM, STENDT CL, VOLLENHOVEN BJ, GAN TE, TIPPING PG (1999) Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 60: 175-180
38. HARRISON DG, CAI H, LANDMESSER U, GRIENDLING KK (2003) Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4: 51-61
39. HANKE H, HANKE S, BRUCK B, BREHME U, GUGEL N, FINKING G, MUCK AO, SCHMAHL FW, HOMBACH V, HAASIS R (1996) Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 121: 129-138
40. HAVERKATE F (2002) Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 39: 109-112.
41. HISHIKAWA K, NAKAKI T, MARUMO T, SUZUKI H, KATO R, SARUTA T (1995) Upregulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS lett 360: 291-293
42. HO KJ, LIAO JK (2002) Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 22: 1952-1961
43. HOETZER GL, STAUFFER BL, IRMIGER HM, NG M, SMITH DT, DESOUZA CA (2003) Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol. [in press]
44. HOIBRAATEN E, OS I, SELJEFLOT I, ANDERSEN TO, HOFSTAD A, SANDSET PM (2000) The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res 98: 19-27
45. HOIBRAATEN E, QVIGSTAD E, ANDERSEN TO, MOWINCKEL MC, SANDSET PM (2001) The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost 85: 775-781
46. HOLSCHERMANN H, TERHALLE HM, ZAKEL U, MAUS U, PARVIZ B, TILLMANNS H, HABERBOSCH W (1999) Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb Haemost 82: 1614-1620
47. HULLEY S, GRADY D, BUSH T, FURBERG C, HERRINGTON D, RIGGS B, VITTINGHOFF E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAM. 280: 605-613
48. HUO Y, LEY K (2001) Adhesion molecules and atherogenesis. Acta Physiol Scand 173: 35-43
49. IAFRATI MD, KARAS RH, ARONOVITZ M, KIM S, SULLIVAN TR, LUBAHN DB, ODONNELL TF, KORACH KS, MENDELSOHN ME (1997) Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med 3: 545-548
50. IMTHURN B, ROSSELLI M, JAEGER AW, KELLER PJ, DUBEY RK (1997) Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 82: 388-394
51. KAMPHUISEN PW, EIKENBOOM JC, ROSENDAAL FR, KOSTER T, BLANN AD, VOS HL, BERTINA RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115: 156-158
52. KHRENOV AV, ANANYEVA NM, GRIFFIN JH, SAENKO EL (2002a) Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 12: 317-324
53. KHRENOV AV, SARAFANOV A, ANANYEVA N, KOUIAVSKAIA D, SHIMA M, SCHWINN H, JOSIC D, SAENKO E (2002b) Molecular basis for different ability of low-density and high-density lipoproteins to support activity of the intrinsic Xase complex. Thromb Res 105: 87-93
54. KLUFT C (2000) Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. Curr Med Chem 7: 585-591
55. KOH KK (2002) Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Int J Hematol 76 Suppl 2: 44-46
56. KOH KK, JIN DK, YANG SH, LEE SK, HWANG HY, KANG MH, KIM W, KIM DS, CHOI IS, SHIN EK (2001) Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103: 1961-1966
57. KOSTER T, BLANN AD, BRIET E, VANDENBROUCKE JP, ROSENDAAL FR (1905) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345: 152-155
58. KNOPP RH (1997) Estrogen, female gender, and heart disease. In: Topol E, Ed. Textbook of cardiovascular medicine: Preventive cardiology. New York: Lippincott-Raven, pp:195-218
59. LASZIK Z, CARSON CW, NADASDY T, JOHNSON LD, LERNER MR, BRACKETT DJ, ESMON CT, SILVA FG (1994) Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Lab Invest 70: 862-867
60. LEE RT, YAMAMOTO C, FENG Y, POTTER-PERIGO S, BRIGGS WH, LANDSCHULZ KT, TURI TG, THOMPSON JF, LIBBY P, WIGHT TN (2001) Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem 276: 13847-13851
61. LIBBY P (2002a) Inflammation in atherosclerosis. Nature 420: 868-874
62. LIBBY P, RIDKER PM, MASERI A (2002b) Inflammation and atherosclerosis. Circulation 105: 1135-1143
63. LINDER V, KIM SK, KARAS RH, KUIPER GG, GUSTAFSSON JA, MENDELSOHN ME (1998) Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 83: 224-229
64. LOWE GD, UPTON MN, RUMLEY A, MCCONNACHIE A, OREILLY DS, WATT GC (2001) Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 86: 550-556.
65. LUYER MD, KHOSLA S, OWEN WG, MILLER VM (2001) Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86: 3629-3634
66. MALLAT Z, HUGEL B, OHAN J, LESECHE G, FREYSSINET JM, TEDGUI A (1999) Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99: 348-353
67. MANN KG (1999) Biochemistry and physiology of blood coagulation. Thromb Haemostasis 82: 165-174
68. MEDINA R, CARDONA-SANCLEMENTE LE, BORN GVR, BROWN MJ (1997). Effect of deoxycorticosterone acetate (DOCA) on blood pressure in relation to accumulation of low density lipoprotein and fibrinogen by aorta and other tissues of normotensive Wistar rats. J Hypertens 15: 531-536
69. MENDELSOHN ME, KARAS RH (1999) The protective effects of estrogen on the cardiovascular system. N Eng J Med 340: 1801-1811
70. MORENO PR, BERNARDI VH, LOPEZ-CUELLAR J, MURCIA AM, PALACIOS IF, GOLD HK, MEHRAN R, SHARMA SK, NEMERSON Y, FUSTER V, FALLON JT (1996) Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94: 3090-3097
71. MOYER MP, TRACY RP, TRACY PB, VANTVEER C, SPARKS CE, MANN KG (1998) Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 18: 458-465
72. MUECK AO, SEEGER H (2003) Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung 53: 1-11
73. Multiple risk factor intervention trial research group (1982) Multiple risk factor intervention trial intervention trial: risk factor changes in mortality results. JAMA 248: 1465-1470
74. MURRAY CJ, LOPEZ AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442
75. NATHAN L, CHAUDHURI G (1997) Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 37: 477-515
76. NODE K, KITAKAZE M, KOSAKA H, MINAMINO T, FUNAYA H, HORIM (1997) Amelioration of ischemia- and reperfusion-induced myocardial injury by 17β-estradiol: the role of nitric oxide and calcium-activated potassium channels. Circulation 96: 1953-1963
77. NORRIS LA, JOYCE M, OKEEFFE N, SHEPPARD BL, BONNAR J (2002) Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43: 125-133
78. OKURA Y, BRINK M, ITABE H, SCHEIDEGGER KJ, KALANGOS A, DELAFONTAINE P (2000) Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 102: 2680-2686
79. PENN MS, CUI MZ, WINOKUR AL, BETHEA J, HAMILTON TA, DICORLETO PE, CHISOLM GM (2000) Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood 96: 3056-3063
80. PEVERILL RE, TEEDE HJ, SMOLICH JJ, MALAN E, KOTSOPOULOS D, TIPPING PG, MCGRATH BP (2001) Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (London) 101: 93-99
81. PIERCY KT, DONNELL RL, KIRKPATRICK SS, TIMARAN CH, STEVENS SL, FREEMAN MB, GOLDMAN MH (2002) Effects of estrogen, progesterone, and combination exposure on interleukin-1 beta-induced expression of VCAM-1, ICAM-1, PECAM, and E-selectin by human female iliac artery endothelial cells. J Surg Res 105: 215-219
82. QIAO JH, TRIPATHI J, MISHRA NK, CAI Y, TRIPATHI S, WANG XP, IMES S, FISHBEIN MC, CLINTON SK, LIBBY P, LUSIS AJ, RAJAVASHISTH TB (1997) Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 150: 1687-1699
83. ROSENDAAL FR, BRIET E, STIBBE J, VAN HERPEN G, LEUVEN JA, HOFMAN A, VANDENBROUCKE JP (1990) Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 75: 525-530
84. ROSENDAAL FR, HELMERHORST FM, VANDENBROUCKE JP (2002) Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22: 201-210
85. SACK MN, RADER DJ, CANNON RO (1994) Oestrogen and inhibition of oxidation in lowdensity lipoproteins in postmenopausal women. Lancet 343: 269-270
86. SALOBIR BG, KEBER I, VRABIC L (2002) A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 78: 1178-1183
87. SELJEFLOT I, ARNESEN H, HOFSTAD AE, OS I (2000) Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 83(6): 944-948
88. SIDELMANN JJ, JESPERSEN J, ANDERSEN LF, SKOUBY SO (2003) Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG 110 (6): 541-7
89. SKOUBY SO, GRAM J, ANDERSEN LF, SIDELMANN J, PETERSEN KR, JESPERSEN J (2002) Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 186: 969-977
90. SMITH DC, PRENTICE R, THOMPSON DJ, HERRMANN WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293: 1164-1167
91. SRAMEK A, REIBER JH, GERRITS WB, ROSENDAAL FR (2001) Decreased coagulability has no clinical relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 104: 762-767
92. STEVENSON JC (2000) Cardiovascular effects of oestrogens. J Steroid Biochem Mol Biol 74: 387-393
93. STORK S, BAUMANN K, VONSCHACKY C, ANGERER P (2002a) The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res 53: 642-649
94. STORK S, VONSCHACKY C, ANGERER P (2002b) The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 165: 301-307
95. SUDHIR K, CHOU TM, CHATTERJEE K, SMITH EP, WILLIAMS TC, KANE JP, MALLOY MJ, KORACH KS, RUBANYI GM (1997a) Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96: 3774-3777
96. SUDHIR K, CHOU TM, MESSINA LM, HUTCHINSON SJ, KORACH KS, CHATTERJEE K, RUBANYI GM (1997b) Endothelial disfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349: 1146-1147
97. SULLIVAN TR, KARAS RH, ARONOVITZ M, FALLER GT, ZIAR JP, SMITH JJ, ODONNELL TF, MENDELSOHN ME (1995) Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96: 2482-2488
98. TEDESCHI-REINER E, REINER Z (2001) Estrogens and risks for onset of atherosclerosis. Lijec Vjesn 123: 135-141
99. TOPPER JN, CAI J, FALB D, GIMBRONE MA (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxigenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417-10422
100. TOSCHI V, GALLO R, LETTINO M, FALLON JT, GERTZ SD, FERNANDEZ-ORTIZ A, CHESEBRO JH, BADIMON L, NEMERSON Y, FUSTER V, BADIMON JJ (1997) Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95: 594-599
101. TRIEMSTRA M, ROSENDAAL FR, SMIT C, VANDERPLOEG HM, BRIET E (1995) Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 123: 823-827
102. VANBAAL WM, EMEIS JJ, KENEMANS P, KESSEL H, PETERS-MULLER ER, SCHALKWIJK CG, VANDERMOOREN MJ, STEHOUWER CD (1999a) Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 29: 913-921
103. VANBAAL WM, KENEMANS P, EMEIS JJ, SCHALKWIJK CG, MIJATOVIC V, VANDERMOOREN MJ, VISCHER UM, STEHOUWER CD (1999b) Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 71: 663-670
104. VANBAAL WM, KENEMANS P, VANDERMOOREN MJ, KESSEL H, EMEIS JJ, STEHOUWER CD (1999c) Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 81: 925-928
105. VANDENBROUCKE JP, ROSING J, BLOEMENKAMP KW, MIDDELDORP S, HELMERHORST FM, BOUMA BN, ROSENDAAL FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344: 1527-1535
106. VAHKAVAARA S, SILVEIRA A, HAKALA-ALAPIETILA T, VIRKAMAKI A, HOVATTA O, HAMSTEN A, TASKINEN MR, YKI-JARVINEN H (2001) Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85: 619-625
107. WASSERTHEIL-SMOLLER S, HENDRIX SL, LIMACHER M, HEISS G, KOOPERBERG C, BAIRD A, KOTCHEN T, CURB JD, BLACK H, ROSSOUW JE, ARAGAKI A, SAFFORD M, STEIN E, LAOWATTANA S, MYSIW WJ (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289: 2673-2684
108. WHITE RE, DARKOW DJ, LANG JL (1995) Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 77: 936-942
109. WHITE RE, SHELTON J, CHEN SJ, DARLEY-USMAR V, ALLEN L, NABORS C, SANDERS PW, CHEN YF, OPARIL S (1997) Estrogen restores endothelial cell function in an experimental model of vascular injury, Circulation 96: 1624-1630
110. WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D (1989) Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86: 2839-2843
111. WINTERGERST ES, JELK J, RAHNER C, ASMIS R (2000) Apoptosis induced by oxidized low-density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur J Biochem 267: 6050-6059
112. World health organization (1995) Oral contraceptive pills and the risk of venous thromboembolism. Prog Hum Reprod Res 39: 2-3
113. World health organization (1997) WHO scientific group meeting on cardiovascular disease and steroid hormone contraceptives. Wkly Epidemiol Rec 72 361-363
114. YOKOYA K, TAKATSU H, SUZUKI T, HOSOKAWA H, OJIO S, MATSUBARA T, TANAKA T, WATANABE S, MORITA N, NISHIGAKI K, TAKEMURA G, NODA T, MINATOGUCHI S, FUJIWARA H (1999) Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation 100: 903-909
115. ZANGER D, YANG BK, ARDANS J, WACLAWIW MA, CSAKO G, WAHL LM, CANNON RO (2000) Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 36: 1797-1802
116. ZHAI P, EURELL TE, COOKE PS, LUBAHN DB, GROSS DR (2000) Myocardial ischemia-reperfusion injury in estrogen receptor-α knockout and wild-type mice. Am J Physiol 279: H1640-H1647
117. ZHU X, BONET B, GILLENWATER H, KNOPP R (1999) Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 222: 214-221
118. ZHU Y, BIAN Z, LU P, KARAS RH, BAO L, COX D, HODGIN J, SHAUL PW, THOREN P, SMITHIES O, GUSTAFSSON JA, MENDELSSOHN ME (2002) Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Sci 295: 505-508